Prot# MA25522: A Randomized, Double-Blind, Parallel-Group Study Of The Reduction Of Signs And Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both In Combination With MTX, In Patients With Moderate To Severe Active Rheumatoid Arthritis And A

Project: Research project

Project Details

StatusFinished
Effective start/end date9/6/11 → 9/6/14

Funding

  • PharmaNet, Inc. (MA25522 // MA25522)
  • Genentech, Inc (MA25522 // MA25522)